Therapeutic cysteine protease inhibitors: a patent review (2018–present)

References

• Verma S, Dixit R, Pandey KC. Cysteine proteases: modes of activation and future prospects as pharmacological targets. Front Pharmacol. 2016;7:107. doi: 10.3389/fphar.2016.00107
   PubMed Web of Science ®Google Scholar
• Gupta SP, Gupta SD. Cancer-leading proteases: an introduction. In: Gupta SP, editor. Cancer-leading proteases - structures, functions, and inhibition. London: Elsevier; 2020. p. 1–11. and reference there in cited.
   Google Scholar
• Solberg R, Lunde NN, Forbord KM, et al. The mammalian cysteine protease legumain in health and disease. Int J Mol Sci. 2022 Dec 15;23(24):15983. doi: 10.3390/ijms232415983
   PubMed Web of Science ®Google Scholar
• Buttle DJ, Mort JS. Cysteine Proteases. In: Lennarz WJ, Lane MD, editors. Encyclopedia of biological chemistry. Amsterdam: Elsevier; 2013. p. 589–592.
   Google Scholar
• Wang Y, Zhao J, Gu Y, et al. Cathepsin H: molecular characteristics and clues to function and mechanism. Biochem Pharmacol. 2023;212:115585. doi: 10.1016/j.bcp.2023.115585
   PubMed Web of Science ®Google Scholar
• Poole AR, Tiltman KJ, Recklies AD, et al. Differences in secretion of the proteinase cathepsin B at the edges of human breast carcinomas and fibroadenomas. Nature. 1978;273(5663):545–7. doi: 10.1038/273545a0
   PubMed Web of Science ®Google Scholar
• Hasanbasic S, Jahic A, Karahmet E, et al. The role of cysteine protease in alzheimer disease. Mater Sociomed. 2016;28(3):235–38. doi: 10.5455/msm.2016.28.235-238
   PubMedGoogle Scholar
• Shen XB, Chen X, Zhang ZY, et al. Cathepsin C inhibitors as anti-inflammatory drug discovery: challenges and opportunities. Eur J Med Chem. 2021;225:113818. doi: 10.1016/j.ejmech.2021.113818
   PubMed Web of Science ®Google Scholar
• Zhang Z, Hou W, Sun H. Cathepsin C inhibitors. US021/0114983 A1.
   Google Scholar
• Hu G, Xiao Y, Cong M, et al. Methods for treating metastasis with cathepsin c inhibitors. WO2022/053019A1.
   Google Scholar
• Wei S, Liu W, Xu M, et al. Cathepsin F and fibulin-1 as novel diagnostic biomarkers for brain metastasis of non-small cell lung cancer. Br J Cancer. 2022;126(12):1795–805. doi: 10.1038/s41416-022-01744-3
   PubMed Web of Science ®Google Scholar
• Takaya K, Asou T, Kishi K. Cathepsin F is a potential marker for senescent human skin fibroblasts and keratinocytes associated with skin aging. Geroscience. 2023;45(1):427–37. doi: 10.1007/s11357-022-00648-7
   PubMed Web of Science ®Google Scholar
• Drake MT, Clarke BL, Oursler MJ, et al. Cathepsin K inhibitors for osteoporosis: biology, potential clinical utility, and lessons learned. Endocr Rev. 2017;38(4):325–50. doi: 10.1210/er.2015-1114. and references therein.
   PubMed Web of Science ®Google Scholar
• Verbovšek U, Van Noorden CJ, Lah TT. Complexity of cancer protease biology: cathepsin K expression and function in cancer progression. Semin Cancer Biol. 2015;35:71–84. doi: 10.1016/j.semcancer.2015.08.010
   PubMed Web of Science ®Google Scholar
• Lu J, Wang M, Wang Z, et al. Advances in the discovery of cathepsin K inhibitors on bone resorption. J Enzyme Inhib Med Chem. 2018;33(1):890–904. doi: 10.1080/14756366.2018.1465417
   PubMed Web of Science ®Google Scholar
• Mijanović O, Jakovleva A, Branković A, et al. Cathepsin K in pathological conditions and new therapeutic and diagnostic perspectives. Int J Mol Sci. 2022;23(22):13762. doi: 10.3390/ijms232213762
   PubMed Web of Science ®Google Scholar
• Duong LT, Wesolowski GA, Leung P, et al. Efficacy of a cathepsin K inhibitor in a preclinical model for prevention and treatment of breast cancer bone metastasis. Mol Cancer Ther. 2014;13(12):2898–909. doi: 10.1158/1535-7163.MCT-14-0253
   PubMed Web of Science ®Google Scholar
• Sudhan DR, Siemann DW. Cathepsin L targeting in cancer treatment. Pharmacol Ther. 2015;155:105–16. doi: 10.1016/j.pharmthera.2015.08.007
   PubMed Web of Science ®Google Scholar
• Liu T, Luo S, Libby P, et al. Cathepsin L-selective inhibitors: a potentially promising treatment for COVID-19 patients. Pharmacol Ther. 2020;213:107587. doi: 10.1016/j.pharmthera.2020.107587
   PubMed Web of Science ®Google Scholar
• Velasco G, Ferrando AA, Puente XS, et al. Human cathepsin O. Molecular cloning from a breast carcinoma, production of the active enzyme in Escherichia coli, and expression analysis in human tissues. J Biol Chem. 1994;269(43):27136–42. doi: 10.1016/S0021-9258(18)47135-9
   PubMed Web of Science ®Google Scholar
• McDowell SH, Gallaher SA, Burden RE, et al. Leading the invasion: the role of Cathepsin S in the tumour microenvironment. Biochim Biophys Acta Mol Cell Res. 2020;1867(10):118781. doi: 10.1016/j.bbamcr.2020.118781
   PubMed Web of Science ®Google Scholar
• Bararia D, Hildebrand JA, Stolz S, et al. Cathepsin S alterations induce a tumor-promoting immune microenvironment in follicular lymphoma. Cell Rep. 2020;31(5):107522. doi: 10.1016/j.celrep.2020.107522
   PubMed Web of Science ®Google Scholar
• Fuchs N, Meta M, Schuppan D, et al. Novel opportunities for cathepsin S inhibitors in cancer immunotherapy by nanocarrier-mediated delivery. Cells. 2020;9(9):2021. doi: 10.3390/cells9092021
   PubMed Web of Science ®Google Scholar
• Lecaille F, Chazeirat T, Saidi A, et al. Cathepsin V: molecular characteristics and significance in health and disease. Mol Aspects Med. 2022;88:101086. doi: 10.1016/j.mam.2022.101086
   PubMed Web of Science ®Google Scholar
• Li J, Chen Z, Kim G, et al. Cathepsin W restrains peripheral regulatory T cells for mucosal immune quiescence. Sci Adv. 2023;9(28):eadf3924. doi: 10.1126/sciadv.adf3924
   PubMed Web of Science ®Google Scholar
• Günther SC, Martínez-Romero C, Sempere Borau M, et al. Proteomic identification of potential target proteins of cathepsin W for its development as a drug target for influenza. Microbiol Spectr. 2022;10(4):e0092122. doi: 10.1128/spectrum.00921-22
   PubMed Web of Science ®Google Scholar
• Khojasteh-Leylakoohi F, Mohit R, Khalili-Tanha N, et al. Down regulation of Cathepsin W is associated with poor prognosis in pancreatic cancer. Sci Rep. 2023;13(1):16678. doi: 10.1038/s41598-023-42928-y
   PubMed Web of Science ®Google Scholar
• Dolenc I, Štefe I, Turk D, et al. Human cathepsin X/Z is a biologically active homodimer. Biochim Biophys Acta Proteins Proteom. 2021;1869(2):140567. doi: 10.1016/j.bbapap.2020.140567
   PubMed Web of Science ®Google Scholar
• Nandi D, Tahiliani P, Kumar A, et al. The ubiquitin-proteasome system. J Biosci. 2006;31(1):137–55. doi: 10.1007/BF02705243
   PubMed Web of Science ®Google Scholar
• Gao G, Luo H. The ubiquitin-proteasome pathway in viral infections. Can J Physiol Pharmacol. 2006;84(1):5–14. doi: 10.1139/y05-144
   PubMed Web of Science ®Google Scholar
• Rubinsztein DC. The roles of intracellular protein-degradation pathways in neurodegeneration. Nature. 2006;443(7113):780–6. doi: 10.1038/nature05291
   PubMed Web of Science ®Google Scholar
• Corn JE, Vucic D. Ubiquitin in inflammation: the right linkage makes all the difference. Nat Struct Mol Biol. 2014;21(4):297–300. doi: 10.1038/nsmb.2808
   PubMed Web of Science ®Google Scholar
• Nicholson B, Suresh Kumar KG. The multifaceted roles of USP7: new therapeutic opportunities. Cell Biochem Biophys. 2011;60(1–2):61–8. doi: 10.1007/s12013-011-9185-5
   PubMed Web of Science ®Google Scholar
• Hoeller D, Hecker CM, Dikic I. Ubiquitin and ubiquitin-like proteins in cancer pathogenesis. Nat Rev Cancer. 2006;6(10):776–88. doi: 10.1038/nrc1994
   PubMed Web of Science ®Google Scholar
• Reyes-Turcu FE, Ventii KH, Wilkinson KD. Regulation and cellular roles of ubiquitin-specific deubiquitinating enzymes. Annu Rev Biochem. 2009;78:363–397.
   PubMed Web of Science ®Google Scholar
• Kitamura H. Ubiquitin-specific proteases (USPs) and metabolic disorders. Int J Mol Sci. 2023;24(4):3219.
   PubMed Web of Science ®Google Scholar
• Cruz L, Soares P, Correia M. Ubiquitin-specific proteases: players in cancer cellular processes. Pharmaceuticals (Basel). 2021;14(9):848. doi: 10.3390/ph14090848
   PubMedGoogle Scholar
• Chauhan D, Tian Z, Nicholson B, et al. A small molecule inhibitor of ubiquitin-specific protease-7 induces apoptosis in multiple myeloma cells and overcomes bortezomib resistance. Cancer Cell. 2012;22(3):345–58. doi: 10.1016/j.ccr.2012.08.007
   PubMed Web of Science ®Google Scholar
• Cummins JM, Rago C, Kohli M, et al. Tumour suppression: disruption of HAUSP gene stabilizes p53. Nature. 2004;428(6982):1–486.
   PubMed Web of Science ®Google Scholar
• Reverdy C, Conrath S, Lopez R, et al. Discovery of specific inhibitors of human USP7/HAUSP deubiquitinating enzyme. Chem Biol. 2012;19(4):467–77. doi: 10.1016/j.chembiol.2012.02.007
   PubMedGoogle Scholar
• Pal A, Donato NJ. Ubiquitin-specific proteases as therapeutic targets for the treatment of breast cancer. Breast Cancer Res. 2014;16(5):461. doi: 10.1186/s13058-014-0461-3
   PubMed Web of Science ®Google Scholar
• Liu X, Balaraman K, Lynch CC, et al. Novel ubiquitin specific protease-13 inhibitors alleviate neurodegenerative pathology. Metabolites. 2021;11(9):622. doi: 10.3390/metabo11090622
   PubMed Web of Science ®Google Scholar
• Li YC, Cai SW, Shu YB, et al. USP15 in cancer and other diseases: from diverse functionsto therapeutic targets. Biomedicines. 2022;10(2):474. doi: 10.3390/biomedicines10020474
   PubMed Web of Science ®Google Scholar
• Lee JG, Takahama S, Zhang G, et al. Unconventional secretion of misfolded proteins promotes adaptation to proteasome dysfunction in mammalian cells. Nat Cell Biol. 2016;18(7):765–76. doi: 10.1038/ncb3372
   PubMed Web of Science ®Google Scholar
• Bédard N, Jammoul S, Moore T, et al. Inactivation of the ubiquitin-specific protease 19 deubiquitinating enzyme protects against muscle wasting. FASEB J. 2015;29(9):3889–98. doi: 10.1096/fj.15-270579
   PubMed Web of Science ®Google Scholar
• Jeusset LM, Guppy BJ, Lichtensztejn Z, et al. Reduced USP22 expression impairs mitotic removal of H2B monoubiquitination, alters chromatin compaction and induces chromosome instability that may promote oncogenesis. Cancers (Basel). 2021;13(5):1043. doi: 10.3390/cancers13051043
   PubMed Web of Science ®Google Scholar
• Ren X, Jiang M, Ding P, et al. Ubiquitin-specific protease 28: the decipherment of its dual roles in cancer development. Exp Hematol Oncol. 2023;12(1):27. doi: 10.1186/s40164-023-00389-z
   PubMed Web of Science ®Google Scholar
• Jin Z, Du X, Xu Y, et al. Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors. Nature. 2020;582(7811):289–93. doi: 10.1038/s41586-020-2223-y
   PubMed Web of Science ®Google Scholar
• Capasso C, Nocentini A, Supuran CT. Protease inhibitors targeting the main protease and papain-like protease of coronaviruses. Expert Opin Ther Pat. 2021;31(4):309–324. doi: 10.1080/13543776.2021.1857726
   PubMed Web of Science ®Google Scholar
• Brian Chia CS, Pheng Lim S. A patent review on SARS Coronavirus Papain-Like protease (PLpro) inhibitors. ChemMedchem. 2023;e202300216(16). doi: 10.1002/cmdc.202300216
   Google Scholar
• Li G, Hilgenfeld R, Whitley R, et al. Therapeutic strategies for COVID-19: progress and lessons learned. Nat Rev Drug Discov. 2023;22(6):449–475. doi: 10.1038/s41573-023-00672-y
   PubMed Web of Science ®Google Scholar
• Yang J, Lin X, Xing N, et al. Structure-based discovery of novel nonpeptide inhibitors targeting SARS-CoV-2 Mpro. J Chem Inf Model. 2021;61(8):3917–3926. doi: 10.1021/acs.jcim.1c00355
   PubMed Web of Science ®Google Scholar
• Amin SA, Banerjee S, Ghosh K, et al. Protease targeted COVID-19 drug discovery and its challenges: insight into viral main protease (mpro) and papain-like protease (PLpro) inhibitors. Bioorg Med Chem. 2021;29:115860. doi: 10.1016/j.bmc.2020.115860
   PubMedGoogle Scholar
• Tumskiy RS, Tumskaia AV, Klochkova IN, et al. SARS-CoV-2 proteases Mpro and PLpro: design of inhibitors with predicted high potency and low mammalian toxicity using artificial neural networks, ligand-protein docking, molecular dynamics simulations, and ADMET calculations. Comput Biol Med. 2023;153:106449. doi: 10.1016/j.compbiomed.2022.106449
   PubMed Web of Science ®Google Scholar
• Rawat A, Roy M, Jyoti A, et al. Cysteine proteases: Battling pathogenic parasitic protozoans with omnipresent enzymes. Microbiol Res. 2021;249:126784. doi: 10.1016/j.micres.2021.126784
   PubMedGoogle Scholar
• Cianni L, Feldmann CW, Gilberg E, et al. Can cysteine protease cross-class inhibitors achieve selectivity? J Med Chem. 2019;62(23):10497–525. doi: 10.1021/acs.jmedchem.9b00683
   PubMed Web of Science ®Google Scholar
• Wang X, Luo H, Zhang R, et al. Application of pirfenidone or pharmaceutically acceptable salt thereof in preparation of medicine for preventing and/or treating novel coronavirus inflammation. CN2020/111481547.
   Google Scholar
• Schurdak ME, Vogt A, Stern A, et al. Compounds for the treatment of a disease or disorder, methods for identifying said compounds. WO2022/159787.
   Google Scholar
• Huang H, Zhang G, Tang J, et al. Use of a PLpro protein inhibitor in a medicament for the treatment or prevention of a novel coronavirus infection. CN2020/112022855.
   Google Scholar
• Fu Z, Huang B, Tang J, et al. The complex structure of GRL0617 and SARS-CoV-2 PLpro reveals a hot spot for antiviral drug discovery. Nat Commun. 2021;12(1):488. doi: 10.1038/s41467-020-20718-8
   PubMed Web of Science ®Google Scholar
• Ma C, Wang J. Validation and Invalidation of SARS-CoV-2 Papain-like Protease Inhibitors. ACS Pharmacol Transl Sci. 2022;5(2):102–9. doi: 10.1021/acsptsci.1c00240
   PubMedGoogle Scholar
• Han K, Jia Y Application of succimer in preparation of anti-coronavirus infection medicine and medicine. CN2022/114246854.
   Google Scholar
• Han K, Jia Y, Wang Y Application of PX-12 in preparation of coronavirus papaya-like protease PLPro inhibitor drug. CN2022/114617877.
   Google Scholar
• Huber K, Patel P, Zhang L, et al. 2-[(1-methylpropyl)dithio]-1H-imidazole inhibits tubulin polymerization through cysteine oxidation. Mol Cancer Ther. 2008;7(1):143–51. doi: 10.1158/1535-7163.MCT-07-0486
   PubMed Web of Science ®Google Scholar
• Ma C, Hu Y, Townsend JA, et al. Ebselen, disulfiram, Carmofur, PX-12, Tideglusib, and shikonin are nonspecific promiscuous SARS-CoV-2 main protease inhibitors. ACS Pharmacol Transl Sci. 2020;3(6):1265–77. doi: 10.1021/acsptsci.0c00130
   PubMedGoogle Scholar
• Han K, Jia Y, Wang Y Application of tideglusib in preparation of coronavirus papaya-like protease PLpro inhibitor drug. CN2022/114432306.
   Google Scholar
• Tan H, Ma C, Wang J. Invalidation of dieckol and 1,2,3,4,6-pentagalloylglucose (PGG) as SARS-CoV-2 main protease inhibitors and the discovery of PGG as a papain-like protease inhibitor. Med Chem Res. 2022;31(7):1147–1153. doi: 10.1007/s00044-022-02903-0
   PubMed Web of Science ®Google Scholar
• Han H, Wang Y, Jia Y, et al. Application of thiamine in preparation of coronavirus papain inhibitor and coronavirus infection resistant medicine. CN2022/114469954.
   Google Scholar
• Han K, Wang Y, Jia Y, et al. Application of pantoprazole in preparation of products for inhibiting coronavirus and medicines for resisting coronavirus infection. CN2022/114504575.
   Google Scholar
• Fallon JN, Heil M, Fallon JJ, et al. Methods of prophylaxis of coronavirus infection and treatment of coronaviruses. WO2022/056103.
   Google Scholar
• Setz C, Schubert U Inhibitors of human deubiquitinases for the treatment of coronaviral infections. WO2021/170290.
   Google Scholar
• Wilen C Compounds and compositions for treating, ameliorating, and/or preventing sars-cov-2 infection and/or complications thereof. WO2021/247367.
   Google Scholar
• Cho CC, Li SG, Lalonde TJ, et al. Drug repurposing for the SARS-CoV-2 papain-like protease [published correction appears in ChemMedChem. 2022 Mar 4;17(5): e202200053]. ChemMedchem. 2022;17(1):e202100455.
   PubMed Web of Science ®Google Scholar
• Xu X, Wan S, Liu W, et al. Isothia (selenium) azolone derivative and application thereof in anti-coronavirus drugs. CN2021/113200978.
   Google Scholar
• Tsai C, Hung M, Chen Y, et al. Use of disulfiram for treating infection of SARS-COV-2. US2021/0386695.
   Google Scholar
• Bai F, Liu H, Xu Y, et al. Application of heterocyclic compound. CN2022/114014824.
   Google Scholar
• Janetka JW, Ledford BE, Mullican MD Pentacyclic compounds useful as inhibitors of hepatitis c virus ns3 helicase. WO2000/024725.
   Google Scholar
• Fawzi AB, Macdonald D, Benbow LL, et al. SCH-202676: an allosteric modulator of both agonist and antagonist binding to G protein-coupled receptors. Mol Pharmacol. 2001;59(1):30–37. doi: 10.1124/mol.59.1.30
   PubMed Web of Science ®Google Scholar
• van den Nieuwendijk AM, Pietra D, Heitman L, et al. Synthesis and biological evaluation of 2,3,5-substituted [1,2,4]thiadiazoles as allosteric modulators of adenosine receptors. J Med Chem. 2004;3(3):663–672.
   Google Scholar
• Lanzafame A, Christopoulos A. Investigation of the interaction of a putative allosteric modulator, N-(2,3-diphenyl-1,2,4-thiadiazole-5-(2H)-ylidene) methanamine hydrobromide (SCH-202676), with M1 muscarinic acetylcholine receptors. J Pharmacol Exp Ther. 2004;308(3):830–837. doi: 10.1124/jpet.103.060590
   PubMed Web of Science ®Google Scholar
• Ren P, Yu C, Zhang R, et al. Discovery, synthesis and mechanism study of 2,3,5-substituted [1,2,4]-thiadiazoles as covalent inhibitors targeting 3C-Like protease of SARS-CoV-2. Eur J Med Chem. 2023;249:115129. doi: 10.1016/j.ejmech.2023.115129
   PubMedGoogle Scholar
• Akaike T, Takagi S, Sugiura H, et al. Medical agent containing active sulfur compounds as main ingredient. WO2021/235494A1.
   Google Scholar
• Barchielli G, Capperucci A, Tanini D. The role of selenium in pathologies: an updated review. Antioxidants. 2022;11(2):251. doi: 10.3390/antiox11020251
   Web of Science ®Google Scholar
• Debnath S, Agarwal A, Kumar NR, et al. Selenium-based drug development for antioxidant and anticancer activity. Future Pharmacology. 2022;2(4):595–607. doi: 10.3390/futurepharmacol2040036
   Google Scholar
• Ali W, Benedetti R, Handzlik J, et al. The innovative potential of seleniumcontaining agents for fighting cancer and viral infections. Drug Discov Today. 2021;26(1):256–263. doi: 10.1016/j.drudis.2020.10.014
   PubMed Web of Science ®Google Scholar
• Hou W, Dong H, Zhang X, et al. Selenium as an emerging versatile player in heterocycles and natural products modification. Drug Discov Today. 2022;27(8):2268–2277. doi: 10.1016/j.drudis.2022.03.020
   PubMed Web of Science ®Google Scholar
• Angeli A, Ferraroni M, Capperucci A, et al. Selenocarbamates as a prodrug-based approach to carbonic anhydrase inhibition. ChemMedchem. 2022;17(11):e202200085. doi: 10.1002/cmdc.202200085
   PubMed Web of Science ®Google Scholar
• Tanini D, Carradori S, Capperucci A, et al. Chalcogenides-incorporating carbonic anhydrase inhibitors concomitantly reverted oxaliplatin-induced neuropathy and enhanced antiproliferative action. Eur J Med Chem. 2021;225:113793. doi: 10.1016/j.ejmech.2021.113793
   PubMed Web of Science ®Google Scholar
• Han K, Jia Y Application of mono-selenoether compound in preparation of anti-coronavirus drugs and drugs. CN2022/114246867.
   Google Scholar
• Han K, Wang Y, Jia Y, et al. Application of diselenide compound as coronavirus papaya protease inhibitor, inhibitor and medicine. CN2021/112156084.
   Google Scholar
• Han K, Wang Y, Jia Y, et al. Application of Ebselen in preparation of coronavirus papain inhibitor and medicine for resisting coronavirus infection. CN2022/114469939.
   Google Scholar
• Weglarz-Tomczak E, Tomczak JM, Talma M, et al. Identification of ebselen and its analogues as potent covalent inhibitors of papain-like protease from SARS-CoV-2. Sci Rep. 2021;11(1):3640. doi: 10.1038/s41598-021-83229-6
   PubMed Web of Science ®Google Scholar
• Suzuki N, Ogra Y, Fukumoto Y, et al. Therapeutic or prophylactic agent for COVID-19 which comprises selenoneine. WO2022/177029A1.
   Google Scholar
• Han K, Jia Y Application of Eflorhithine in preparation of anti-coronavirus infection medicine and medicine. CN2022/114246855.
   Google Scholar
• Han K, Wang Y, Jia Y, et al. Application of Trazodone in preparation of coronavirus papain-like protease PLPro inhibitor drug. CN2020/112043706.
   Google Scholar
• Han K, Wang Y, Jia Y, et al. Application of Phenlzine in preparation of coronavirus papain-like protease inhibitor and coronavirus infection resisting medicine. CN2022/114469914.
   Google Scholar
• Han K, Jia Y, Wang Y Application of Vilanterol in preparation of anti-coronavirus medicines and medicines. CN2022/114617862.
   Google Scholar
• Hanania NA, Feldman G, Zachgo W, et al. The efficacy and safety of the novel long-acting β2 agonist vilanterol in patients with COPD: a randomized placebo-controlled trial. Chest. 2012;142(1):119–127.
   PubMed Web of Science ®Google Scholar
• Han K, Jia Y, Wang Y Coronavirus papaya-like protease PLPro inhibitor Lomustine and application thereof. CN2022/114617864.
   Google Scholar
• Morasca L, Balconi G, Erba E, et al. Cytotoxic effect in vitro and tumour volume reduction in vivo induced by chemotherapeutic agents. Eur J Cancer (1965). 1974;10(10):667–671. doi: 10.1016/0014-2964(74)90006-1
   PubMed Web of Science ®Google Scholar
• Montelione GT, Bafna K, Krug RM, et al. Compositions and methods utilizing protein inhibitors for synergistic inhibition and treatment of SARS-CoV-2. WO2022/076386.
   Google Scholar
• Bafna K, White K, Harish B, et al. Hepatitis C virus drugs that inhibit SARS-CoV-2 papain-like protease synergize with remdesivir to suppress viral replication in cell culture. Cell Rep. 2021;35(7):109133. doi: 10.1016/j.celrep.2021.109133
   PubMed Web of Science ®Google Scholar
• Gammeltoft KA, Zhou Y, Duarte Hernandez CR, et al. Hepatitis C virus protease inhibitors show differential efficacy and interactions with remdesivir for treatment of SARS-CoV-2 in vitro. Antimicrob Agents Chemother. 2021;65(9):e0268020. doi: 10.1128/AAC.02680-20
   PubMed Web of Science ®Google Scholar
• Muturi E, Hong W, Li J, et al. Effects of simeprevir on the replication of SARS-CoV-2 in vitro and in transgenic hACE2 mice. Int J Antimicrob Agents. 2022;59(1):106499. doi: 10.1016/j.ijantimicag.2021.106499
   PubMed Web of Science ®Google Scholar
• Han K, Wang Y, Jia Y, et al. Application of non-peptide compound in preparation of products for inhibiting coronavirus. CN2022/114557990.
   Google Scholar
• Sayuk GS, Tack J. Tegaserod: what’s old is new again. Clin Gastroenterol Hepatol. 2022;20(10):2175–2184.e19. doi: 10.1016/j.cgh.2022.01.024
   PubMed Web of Science ®Google Scholar
• Liu X, Xu X, Yuan W, et al. Use of tegaserod for the preparation of a medicament for the prevention or treatment of coronavirus infection. CN2021/112587522.
   Google Scholar
• Xu Z, Yao H, Xu Y, et al. Application of nelfinavir in preparation of drug for preventing and treating novel coronavirus pneumonia. WO2021/164689.
   Google Scholar
• Tam HH, Kolesky DB, Wong MKC Anti-viral compounds and methods of using same. WO2021/262799.
   Google Scholar
• Pegan S, Durie I, Freitas B, et al. Compositions and methods of treatment for sars-cov-2 through papain protease inhibition. WO2022/072975.
   Google Scholar
• Báez-Santos YM, Barraza SJ, Wilson MW, et al. X-ray structural and biological evaluation of a series of potent and highly selective inhibitors of human coronavirus papain-like proteases. J Med Chem. 2014;57(6):2393–2412. doi: 10.1021/jm401712t
   PubMed Web of Science ®Google Scholar
• Sharma R, Agarwal S Novel amide derivatives. WO 2022/070048.
   Google Scholar
• Wang J, Ma C Small molecule inhibitors of SARS-CoV-2 viral replication and uses thereof. WO2021/207409.
   Google Scholar
• Wang J, Kitamura N, Ma C Compositions and methods for inhibiting m pro protease activity and for preventing and treating sars-cov-2 infection. WO 2022/119756A1.
   Google Scholar
• Richter W, Abbas M, Weber L, et al. Mpro cysteine protease inhibitors. WO 2022/040186A1.
   Google Scholar
• Meek TD, Li L, Tseng CK, et al. Inhibitors of cysteine proteases. WO 2022/187491A1.
   Google Scholar
• Jorgensen WL Non-covalent inhibitors of the main protease of SARS-CoV-2 and methods of use. WO2022/150584A1.
   Google Scholar
• Buzard DJ, Keung W, Kumar DV, et al. Inhibitors of cysteine proteases and methods of use thereof. WO2023/023631A1.
   Google Scholar
• Arnold LD, Kerung W Inhibitors of cysteine proteases and methods of use thereof. WO 2022/221686A1.
   Google Scholar
• Wang J Compositions and methods for inhibiting Mpro and PLpro protease activity and for preventing and treating SARS-CoV-2 infection. US 2022/0332683A1.
   Google Scholar
• Fu L, Ye F, Feng Y, et al. Both boceprevir and GC376 efficaciously inhibit SARS-CoV-2 by targeting its main protease. Nat Commun. 2020;11(1):4417. doi: 10.1038/s41467-020-18233-x
   PubMed Web of Science ®Google Scholar
• Lo JM, Huang C, Wu YB, et al. Compounds and methods for prevention and treatment of coronavirus infections. US 2021/0338690A1.
   Google Scholar
• Wu YB, Lo JM, Huang C, et al. Compounds and methods for prevention and treatment of virus infections. WO 2022/047147A1.
   Google Scholar
• Khan MA Spiro-lactam compounds and methods of treating viral infections using the same. US 2023/0210851A1.
   Google Scholar
• Meek TD, Tseng C-T, Drelich A, et al. Inhibitors of SARS-CoV-2 infection and uses thereof. WO2022/047054A2.
   Google Scholar
• Kos J, Mitrovic A, Sosoc I, et al. 8-hydroxyquinoline cysteine protease inhibitors for use in the prevention and/or treatment of a corona virus disease. WO2022/117724A1
   Google Scholar
• Kane CD, Soloveva V, Bavari S, et al. Cathepsin inhibitors for preventing or treating viral infections. WO2021/191875A1.
   Google Scholar
• Frueh F, Maneval D, Daley TE Viral entry inhibitors and RNA polymerase inhibitors. WO 2021/203055A1.
   Google Scholar
• O’dowd C, Harrison T, Hewitt P, et al. Piperidinderivate als hemmer der ubiquitinspezifischen protease 7. EP4026832A1.
   Google Scholar
• Buhrlane S, Liu X Usp7 inhibition. WO2020/086595A1.
   Google Scholar
• Wolberger C, Morgan MT, Suga H Cyclic peptide inhibitors of USP22. WO2022/232567A2.
   Google Scholar
• Moussa C, Wolf C, Kaluvu B Usp13 inhibitors and methods of use thereof. WO2022/155427A1.
   Google Scholar
• Buhrlage S, Varca A, Hu B Fused tricyclic pyrimidine-thieno-pyridine small molecule inhibitors of ubiquitin-specific protease 28. WO2022/035806A1.
   Google Scholar
• Rountree JSS, Whitehead SK, Sheperd SD, et al. Pharmaceuticals compounds as inhibitors of ubiquitin specific protease 19 (usp19). WO2022/200523A1.
   Google Scholar
• Lee KH, Kronbichler A, Park DD, et al. Neutrophil extracellular traps (NETs) in autoimmune diseases: A comprehensive review. Autoimmun Rev. 2017;16(11):1160–1173.
   PubMed Web of Science ®Google Scholar
• Beemelmanns C, GUO H, Höfgen S, et al. Barnesin a, derivatives and uses thereof. WO2019/170705A1.
   Google Scholar
• Zamyatnin AA, Rudzinska M, Parodi A, et al. Specific peptide inhibitors of cysteine cathepsins. WO2021/251850A1.
   Google Scholar
• Beal R, Sand B, Brunner S, et al. Inhibition of spontaneous metastasis via protein inhibitors of cysteine proteases. WO2019/055884A2.
   Google Scholar
• Gonzalez DJ, Dulai P, Mills R Therapeutic approach for treating inflammatory bowel disease. US202/2395489A1.
   Google Scholar
• Siewinski MZ Inhibitors of cysteine peptidases isolated from natural raw materials and use of the inhibitors in medicine and veterinary medicine. WO2020/167152A1.
   Google Scholar
• Hao Z, Gong S, Shen D, et al. Small molecule inhibitor of cathepsin c and medicinal use thereof. WO2022/117059 A1.
   Google Scholar
• Anderskewitz R, Binder F, Grauert M, et al. Methods for treating pulmonary emphysema using substituted 2-aza-bicyclo[2.2.1]heptane-3-carboxylic acid (benzyl-cyano-methyl)-amides inhibitors of cathepsin c. US2023/0310373 A1.
   Google Scholar
• Walensky LD, Bird GH, Guerra R, et al. Selective targeting of apoptosis proteins by structurally-stabilized and/or cysteine-reactive noxa peptides. WO2019/118719A1.
   Google Scholar
• Beroukhim R, Mermel CH, Porter D, et al. The landscape of somatic copy-number alteration across human cancers. Nature. 2010;463(7283):899–905. doi: 10.1038/nature08822
   PubMed Web of Science ®Google Scholar
• Liu X, Chen X, Shi J, et al. Pyrimidine-2,4-diamine compound and prepareation method and application thereof. US2023/0150947 A1.
   Google Scholar
• Methods for enhancing cytotoxic cancer therapy through inhibition of ATG4B. US2021069202A1.
   Google Scholar
• Xu S, Sun L, Huang B, et al. Medicinal chemistry strategies of targeting HIV-1 capsid protein for antiviral treatment. Future Med Chem. 2020;12(14):1281–4. doi: 10.4155/fmc-2020-0084
   PubMed Web of Science ®Google Scholar
• Ren Y, Ma Y, Cherukupalli S, et al. Discovery and optimization of benzenesulfonamides-based hepatitis B virus capsid modulators via contemporary medicinal chemistry strategies. Eur J Med Chem. 2020;206:112714. doi: 10.1016/j.ejmech.2020.112714
   PubMed Web of Science ®Google Scholar
• Zhang L, Wei F, Zhang J, et al. Current medicinal chemistry strategies in the discovery of novel HIV-1 ribonuclease H inhibitors. Eur J Med Chem. 2022;243:114760. doi: 10.1016/j.ejmech.2022.114760
   PubMed Web of Science ®Google Scholar
• Hou L, Zhang Y, Ju H, et al. Contemporary medicinal chemistry strategies for the discovery and optimization of influenza inhibitors targeting vRNP constituent proteins. Acta Pharm Sin B. 2022;12(4):1805–24. doi: 10.1016/j.apsb.2021.11.018
   PubMed Web of Science ®Google Scholar
• Gao S, Huang T, Song L, et al. Medicinal chemistry strategies towards the development of effective SARS-CoV-2 inhibitors. Acta Pharm Sin B. 2022;12(2):581–99. doi: 10.1016/j.apsb.2021.08.027
   PubMed Web of Science ®Google Scholar
• Ding D, Xu S, da Silva-Júnior EF, et al. Medicinal chemistry insights into antiviral peptidomimetics. Drug Discov Today. 2023;28(3):103468. doi: 10.1016/j.drudis.2022.103468
   PubMed Web of Science ®Google Scholar
• Ma Y, Frutos-Beltrán E, Kang D, et al. Medicinal chemistry strategies for discovering antivirals effective against drug-resistant viruses. Chem Soc Rev. 2021;50(7):4514–40. doi: 10.1039/D0CS01084G
   PubMed Web of Science ®Google Scholar